Chief Financial Officer
Mr. Liatos is our Chief Financial Officer. He joins Adgero with over 20 years of experience in operations, corporate finance, private equity and venture capital related to the life sciences industry. Prior to joining Adgero, Mr. Liatos was the Co- Founding Partner at Aceras BioMedical, LLC, a unique healthcare-focused investment firm focused on forming and managing new companies to acquire and develop pre-commercial stage biomedical assets. During his time at Aceras, Mr. Liatos was responsible for the overall formation and business strategy of Aceras and its portfolio companies, as well as evaluating new investments. Mr. Liatos served as the Co-founder and CFO of Huxley Pharmaceuticals, Inc., an Aceras portfolio company acquired by BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), as well as the Co-founder and CFO of Sherrington Pharmaceuticals, Inc., an Aceras portfolio company that develops specialty products for severe pain disorders which was acquired by Sorrento Therapeutics, Inc. (NASDAQ: SRNE). Mr. Liatos also served as the CFO of a life sciences investment fund, Paramount BioSciences, LLC, where his experience included management recruitment, deal structuring and negotiations, investment valuation, financial reporting and corporate transactions, including mergers and acquisitions, private placements and self-registrations for the Paramount portfolio companies. Prior to that, Mr. Liatos served as a Senior Associate at Gefinor (USA), Inc., a New York-based private equity firm and as a Senior Associate in the Financial Reporting and Consolidations group at RJR Nabisco, Inc.
Mr. Liatos earned his B.S. in Business Administration from The Citadel in Charleston, S.C. and began his career as an auditor at Eisner Amper LLP, formerly known as Richard A. Eisner & Company, a regional public accounting firm.
Steve Rychnovsky, PhD
Vice President of Operations and Product Development
Dr. Rychnovsky is our Vice President of Operations and Product Development. He is experienced in all aspects of Adgero's photodynamic therapy. In 2012 Dr. Rychnovsky co-founded Adgero with Dr. Frank Pilkiewicz. Dr. Rychnovsky has played a key role in development of Adgero's business strategy and implementation of plans for the development and commercialization of REM-001.
Dr. Rychnovsky is a former consultant to St. Cloud Investments where he was responsible for the portfolio of assets acquired from Miravant Medical Technologies ("Miravant"), the Company that originally developed Adgero's core technology. Prior to this he was the Cardiovascular Program Manager at Miravant, where he invented key elements of Miravant's cardiovascular technology. Dr. Rychnovsky also served as the Director of Systems and Engineering at Miravant where he managed the team responsible for development of Miravant's photodynamic therapy (PDT) light delivery technology. During his time at Miravant, Dr. Rychnovsky was involved in new product development for its cancer, ophthalmology and cardiovascular programs, including clinical development of REM-001 and related PDT technology.
Dr. Rychnovsky earned a B.S. in electrical engineering from Iowa State University, an M.S. in electrical engineering from the University of Minnesota and has a Ph.D. in photonics from the University of Iowa.
Vice President, Technical Operations
Ms. Edgerly-Pflug is our Vice President of Technical Operations. With over 25 years' in the biotechnology-pharmaceutical industries she has extensive experience in product and process development including scale-up to support commercial operations.
Ms. Edgerly-Pflug has worked on the development and commercialization of a number of complex pharmaceuticals and biologics with a wide range of formulations types and routes of administration. She has extensive experience in product and process development and scale-up from bench to commercial processes, all areas of good manufacturing practice (GMP) compliance, and has developed and implemented quality management systems and improved pre-existing quality systems. During her time at Pflug BioPharm Solutions, she provided strategic direction and implementation to clients in the areas of new technologies, new products, lifecycle initiatives and quality assurance. Ms. Edgerly-Pflug served at Insmed Incorporated, formerly Transave Inc., as VP of Technical Operations and Chemistry, Manufacturing and Controls, and served as the Director of Manufacturing at Ovation Pharmaceuticals Inc., currently Recordati Rare Diseases. Earlier in her career, Laura served as Senior Director of Global Pharmaceutical Development at Biomira, where she was accountable for all staff and activities focused on the development of liposome-based cancer vaccines, proteins, and peptides in support of pre-clinical and clinical studies. Following her initial industrial position as a chemist at Colgate-Palmolive, Laura rose to the rank of Scientist at The Liposome Company where she developed the validation process for the company's lead commercial product Abelcet®.
Ms. Edgerly-Pflug earned a B.S. in Chemistry from Kean College of New Jersey.